Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines

Vaccine

Volumn 29, Issue 22, 2011, Pages 3863-3872

  Capeding, Rosario Z ^a   Luna, Imelda A ^a   Bomasang, Emily ^a   Lupisan, Socorro ^a   Lang, Jean ^b   Forrat, Remi ^b   Wartel, Anh ^c   Crevat, Denis ^b  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b SANOFI PASTEUR   (France)

^c Asia and JPAC Region   (Singapore)

Author keywords

Clinical trial; Dengue vaccine; Flavivirus; Live attenuated vaccine; Phase I

Indexed keywords

DENGUE VACCINE; LIVE ATTENUATED TETRAVALENT DENGUE VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHILD; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DENGUE; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDEMIC DISEASE; FEMALE; FLAVIVIRUS; FOLLOW UP; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PHILIPPINES; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; VIREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; ENDEMIC DISEASES; HUMANS; IMMUNIZATION, SECONDARY; MIDDLE AGED; PHILIPPINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIREMIA; YOUNG ADULT;

EID: 80051666711     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.057     Document Type: Article

References (19)

1. Gubler DJ. Dengue. In: Monath TPM, editor. Epidemiology of arthropod-borne viral disease. Boca Raton, FL: CRC Press; 1988. pp. 223-260.
2. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr 1997;131:516-24.
3. Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet 1998;352:971-7.
4. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections. Postgrad Med J 2004;80:588-601.
5. Meulen J, Grau M, Lenz O, Emmerich P, Schmitz H, Oh F, et al. Isolation and partial characterization of dengue virus type 2 and 4 strains from dengue fever and dengue haemorrhagic fever patients from Mindanao, Republic of Philippines. Trop Med Int Health 2000;5:325-9.
6. World Health Organization. Dengue in the Western Pacific region. http://www.wpro.who.int/health topics/dengue/. Updated September 15, 2010. Accessed September 20, 2010.
7. World Health Organization. Dengue and dengue haemorrhagic fever. Fact sheet number 117. http://www.who.int/mediacentre/ factsheets/fs117/en/print.html. Updated March 2009. Accessed September 20, 2010.
8. Salda LTD, Parquet MDC, Matias RR, Natividad FF, Kobayashi N, Morita K. Molecular epidemiology of dengue 2 viruses in the Philippines: genotype shift and local evolution. Am J Trop Med Hyg 2005;73:796-802.
9. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001;75:7290-304.
10. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000;74:5477-85.
11. Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 2008;151:40-6.
12. Porterfield JS. A plaque technique for the titration of yellow fever virus and antisera. Trans R Soc Trop Med Hyg 1959;53:458-66.
13. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967;99:285-90.
14. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008;21:123-32.
15. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naïve adults. J Infect Dis 2010;201:370-7.
16. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011;30:e9-17.
17. Marcus LC, Froeschle JE, Hill DR, Wolfe MS, Maus D, Connor B, et al. Safety of Typhim Vi vaccine in a postmarketing observational study. J Travel Med 2007;14:386-91.
18. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006;24:1238-41.
19. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009;80:302-11.